N/A N=36 Patch Test of Benzalkonium Chloride Disinfectant Spray
Wound Healing
Primary: Proportion of Participants With Skin Irritation Scores at 24 Hours — 75.0; 91.7; 94.4; 94.4 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
Psoriasis
Primary: Number of Participants in Each Treatment Group With Clinical Cure: Physician's Global Assessment (PGA) Score = 0 or 1 at Day 28 — 13.33; 10.00; 20.69; 37.93 percentage…
Phase 4 N=30 Vapocoolant Spray Used Prior to Intravenous (IV) Insertions
Pain
Primary: Pain Scale Using Visual Analog Scale — 1.13; 1.60 score on a scale
N/A N=40 Evaluation of the Efficacy of 3M Dry Mouth Moisturizing Spray
Xerostomia
Primary: 10 cm Mouth Dryness Visual Analog Score — 4.51; 4.6 cm
N/A N=72 Study Using Spray Skin Protector Versus Conventional Treatment to Prevent Acute Radiodermatitis.
Radiodermatitis · Injury, Radiation
Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants
Phase 3 N=277 A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis
Psoriasis
Primary: Percentage of Participants With Treatment Success According to the Investigator's Global Assessment (IGA) — 21.50; 7.4 percentage of subjects
Phase 3 N=120 Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Clinical Success ITT — 32; 11 participants — p=<0.0001
Phase 4 N=249 Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Who Are Clear/Almost Clear of Plaque Psoriasis From Baseline to End of Treatment Based on the Overall Disease Severity (ODS) Scale — 62; 44…
N/A N=50 A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray
Skin Care
Primary: Participant-perceived Cooling Sensation Immediately Post Product Application — 30.63; 30.15; 25.16 Score on a scale — p=0.0659
N/A N=200 BАbykids Spray In Common Cold
Common Cold · Rhinitis Viral
Primary: The Area Under the Curve (AUC) of the Global Score of the Acute Rhinitis Symptoms Severity Questionnaire (ARSSQ) During First 10 Days of Symptoms - Full Analysis Set…
N/A N=100 Vapocoolant (Pain Ease) Use for Venipuncture
Pain
Primary: Pain Scale on Numeric Rating Scale (NRS) ( 0 to 10) — 1.7; 4.7 units on a scale
N/A N=8 Self-dispersing Liquids as Aerosol Drug Carriers
Cystic Fibrosis
Primary: Uniformity of Aerosol Distribution — -0.05; 0.10 ratio — p=0.07
Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Clinical Success — 18; 3 participants — p=0.0003
Phase 3 N=454 Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
Hot Flashes
Primary: Mean Change in the Number of Moderate to Severe Vasomotor Symptoms Per Day — -5.32; -6.19; -4.76; -8.44 Vasomotor symptoms per day — p=<0.0001
Phase 4 N=58 A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation
Pediculosis Capitis · Lice Infestations · Head Lice
Primary: Proportion of Participants Who Are Completely Free of Live Lice — 0.00; 0.00; .535; .200 proportion of subjects free of live lice — p=.025
N/A N=29 Duration of Effect of Biotene Spray in Patients With Dry Mouth
Dry Mouth
Primary: Mean Duration of Action of Intervention — 27; 26 minutes
Phase 2 N=24 Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study
Psoriasis
Primary: Proportion of Patients in the Study With Hypothalamic Pituitary Adrenal (HPA) Axis Suppression — 2; 3 participants
Phase 2 N=146 A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold
Common Cold
Primary: Reducing Symptoms of a Common Cold — 53; 53; 55; 54 units on a scale
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 4 N=81 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
Scalp Psoriasis
Primary: Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if…
Phase 3 N=302 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
Rhinitis, Allergic, Perennial
Primary: Mean Change From Baseline (Day 1) Over the Entire Treatment Period in Daily, Reflective Total Nasal Symptom Scores (rTNSS) Over 6 Weeks — -2.69; -3.95 Scores on a scale…
Phase 2 N=88 Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
Psoriasis
Primary: Percentage of Participants With Success Rate 1 (SR1) at Week 8 — 4.5; 0.0 percentage of participants
Phase 3 N=394 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Psoriasis
Primary: Percentage of Participants With Success According to the Investigator Global Assessment (IGA) — 19.0; 2.3 percentage of patients — p=<0.001
N/A N=129 Blinded Dry Mouth Spray Crossover Study
Xerostomia · Head and Neck Cancer · Xerostomia Following Radiotherapy
Primary: Oral Dryness — 45.5; 46.6; 52.76; 54.1 units on a scale — p=<0.501
N/A N=81 Buzzy Versus Vapocoolant Spray: Pediatric Needle Pain Relief
Pain
Primary: Faces Pain Scale-Revised (FPS-R) — 4; 2 units on a scale
Phase 3 N=130 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Cancer
Primary: Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30) — 640.3; 399.6 Units on a scale
Phase 4 N=30 Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram
Pain Relief · Analgesia
Primary: Change in Pain Score — 50.6; 70.4 mm — p=0.43
Phase 3 N=127 Fluticasone Nasal Spray Patient Preference Study
Rhinitis, Allergic, Perennial
Primary: Overall Participants Preference for Nasal Spray Based on Selected Product Attributes at the End of Crossover Dosing — 72; 39; 9; 77 Participants — p=0.003
Phase 3 N=327 Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
Perennial Allergic Rhinitis
Primary: Total Preference Composite Score Assessed at the End of the Study. The Total Preference Score is the Standardized Sum of 17 Individual Preference Items — 68.3 scores on…
N/A N=18 Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison
Chronic Sinusitis
Primary: To Measure the Distribution of Nasal Sprays and Drops. — 18; 17; 16; 17 nasal cavities (right and left sides)